|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Shire
gptkb:Nycomed
|
|
gptkbp:CEO
|
gptkb:Christophe_Weber
|
|
gptkbp:country
|
gptkb:Japan
|
|
gptkbp:founded
|
1781
|
|
gptkbp:founder
|
gptkb:Chobei_Takeda_I
|
|
gptkbp:globalPresence
|
over 80 countries
|
|
gptkbp:hasResearchCenter
|
gptkb:Asia
gptkb:Europe
gptkb:Japan
gptkb:United_States
|
|
gptkbp:headquarters
|
gptkb:Osaka,_Japan
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:listedOn
|
gptkb:Nikkei_225
gptkb:TOPIX_Core30
|
|
gptkbp:memberOf
|
gptkb:Japan_Pharmaceutical_Manufacturers_Association
gptkb:European_Federation_of_Pharmaceutical_Industries_and_Associations
|
|
gptkbp:notable_drug
|
gptkb:Alunbrig
gptkb:Cinryze
gptkb:Rozerem
gptkb:Adcetris
gptkb:Mobocertinib
gptkb:Aloxi
gptkb:Colcrys
gptkb:Dexilant
gptkb:Entyvio
gptkb:Firazyr
gptkb:Gammagard
gptkb:Natpara
gptkb:Ninlaro
gptkb:Takhzyro
gptkb:Velcade
gptkb:Vpriv
gptkb:Baxdela
gptkb:Exkivity
Advate
Elaprase
Feiba
Livtencity
Obizur
Replagal
TAK-003 (dengue vaccine)
|
|
gptkbp:numberOfEmployees
|
~49,000
|
|
gptkbp:products
|
vaccines
pharmaceutical drugs
rare disease treatments
gastroenterology medicines
neuroscience medicines
oncology medicines
|
|
gptkbp:revenue
|
3.569 trillion yen (FY2023)
|
|
gptkbp:stockExchange
|
gptkb:Tokyo_Stock_Exchange
|
|
gptkbp:stockSymbol
|
4502
|
|
gptkbp:website
|
https://www.takeda.com/
|
|
gptkbp:bfsParent
|
gptkb:Nuvaxovid
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Takeda (in Japan)
|